Additional expression of the major antioxidant enzymes may have additional benefits in T2DM (56) as well as T1D (57), and this may be another potentially beneficial effect of GHRHR agonists in both major types of diabetes. The gene discussed is GHRHR; the disease is type 2 diabetes mellitus.